These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 35378274)

  • 1. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine.
    Gowd V; Ahmad A; Tarique M; Suhail M; Zughaibi TA; Tabrez S; Khan R
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):624-644. PubMed ID: 35378274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.
    Boone CE; Wang L; Gautam A; Newton IG; Steinmetz NF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1739. PubMed ID: 34296535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial prospects of nano-targeted chemoimmunotherapy.
    Da Silva CG; Rueda F; Löwik CW; Ossendorp F; Cruz LJ
    Biomaterials; 2016 Mar; 83():308-20. PubMed ID: 26796043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.
    Chakraborty K; Tripathi A; Mishra S; Mallick AM; Roy RS
    Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35638450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment.
    Yadav R; Das PP; Sharma S; Sengupta S; Kumar D; Sagar R
    Med Oncol; 2023 Nov; 40(12):347. PubMed ID: 37930458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
    Li S; Bennett ZT; Sumer BD; Gao J
    Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine in Bladder Cancer Therapy.
    Winnicka A; Brzeszczyńska J; Saluk J; Wigner-Jeziorska P
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
    Grimaldi AM; Incoronato M; Salvatore M; Soricelli A
    Nanomedicine (Lond); 2017 Oct; 12(19):2349-2365. PubMed ID: 28868980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
    Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
    Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
    Peng S; Xiao F; Chen M; Gao H
    Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy.
    Zhang Y; Chen X; Hu B; Zou B; Xu Y
    Nanomedicine (Lond); 2024; 19(21-22):1821-1840. PubMed ID: 39011582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects.
    Jiang Y; Wang C; Zu C; Rong X; Yu Q; Jiang J
    Int J Nanomedicine; 2024; 19():9459-9486. PubMed ID: 39371481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancement and Applications of Nanotherapy for Cancer Immune Microenvironment.
    He JJ; Li QQ; Zhao C; Zhou J; Wu J; Zhang HB; Zhao YQ; Zhang HH; Lei TY; Zhao XY; You Z; Song QB; Xu B
    Curr Med Sci; 2023 Aug; 43(4):631-646. PubMed ID: 37558863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted nanomedicine in cisplatin-based cancer therapeutics.
    Han Y; Wen P; Li J; Kataoka K
    J Control Release; 2022 May; 345():709-720. PubMed ID: 35367476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment.
    Gao S; Yang X; Xu J; Qiu N; Zhai G
    ACS Nano; 2021 Aug; 15(8):12567-12603. PubMed ID: 34339170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
    Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
    Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines: Redefining traditional medicine.
    Lu W; Yao J; Zhu X; Qi Y
    Biomed Pharmacother; 2021 Feb; 134():111103. PubMed ID: 33338747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.